Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis

BACKGROUND: The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients with MG...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neurooncol Adv
Главные авторы: Alnahhas, Iyad, Alsawas, Mouaz, Rayi, Appaji, Palmer, Joshua D, Raval, Raju, Ong, Shirley, Giglio, Pierre, Murad, Mohammad Hassan, Puduvalli, Vinay
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Reviews
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596890/
https://ncbi.nlm.nih.gov/pubmed/33150334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa082
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы